glp-1 agonists cancer risk Receptor in Solid Tumour Therapy: Exploring Their Anticancer Potential and Underlying Molecular Pathways glp-1 receptor agonists and cancer

Since isolated primary human islets cannot be cultured for extensive periods of time and exhibit donor-to-donor variability, most groups have historically relied on rodent models and cell lines to robustly understand the genetic and mechanistic components involved in the initiation and progression of T1D

China at 6.8%, India at 6.3%, Germany at 5.8%, France at 5.3%, UK at 4.8%, USA at 4.3%, Brazil at 3.8%

Measurement of Blood Pressure in Humans: A Scientific Statement From the American Heart Association

[ in vitro amyloid-induced neurotoxicity model, suggesting transporter-mediated BBB translocation and enhanced intracellular drug distribution [ Complementary mechanistic insight is provided by recent work on free-radical-scavenging-nanoparticles, including CQDs, which highlights their ability to attenuate neuroinflammation and oxidative stress through ROS scavenging and suppression of lipid peroxidation, thereby positioning CQDs as both therapeutic nanocarriers and active redox modulators [ in vitro and acute in vivo models highlights the need for systematic evaluation of long-term safety, biodistribution, and translational relevance in clinically relevant neurological settings [Table 2

The role of the microbiome in the pathogenesis and treatment of ulcerative colitisA literature review